The current AChE inhibitors are far from adequate to meet the demand for highly effective AD interventions [81] that are urgently needed to improve cognitive functions and/or take advantage of the recently recognized additional anti-neurodegenerative benefits [54,55,56,57,58,59,60,61,62]. Here, ACHE is linked to Alzheimer disease.